Emerging drug design strategies in anti-influenza drug discovery

[1]  R. I. Benhamou,et al.  Targeted Degradation of Structured RNAs via Ribonuclease-Targeting Chimeras (RiboTacs) , 2023, Expert opinion on drug discovery.

[2]  Yongqiang Deng,et al.  PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor , 2023, Virologica Sinica.

[3]  Xinyi Zhou,et al.  Computational drug repurposing by exploiting large-scale gene expression data: Strategy, methods and applications , 2023, Comput. Biol. Medicine.

[4]  S. Mohile,et al.  Association of polypharmacy and potential drug‐drug interactions with adverse treatment outcomes in older adults with advanced cancer , 2023, Cancer.

[5]  Yixian Liao,et al.  Identification of N- and C-3-Modified Laudanosoline Derivatives as Novel Influenza PAN Endonuclease Inhibitors. , 2022, Journal of medicinal chemistry.

[6]  J. Keown,et al.  A structural understanding of influenza virus genome replication. , 2022, Trends in microbiology.

[7]  A. Vilcinskas,et al.  Antiviral Potential of Natural Resources against Influenza Virus Infections , 2022, Viruses.

[8]  Yiyan Fei,et al.  Emerging degrader technologies engaging lysosomal pathways , 2022, Chemical Society reviews.

[9]  Shuwen Liu,et al.  Emerging antiviral therapies and drugs for the treatment of influenza , 2022, Expert opinion on emerging drugs.

[10]  A. Majewska,et al.  Evolution of Influenza Viruses—Drug Resistance, Treatment Options, and Prospects , 2022, International journal of molecular sciences.

[11]  A. Y. Ye,et al.  Generation of a live attenuated influenza A vaccine by proteolysis targeting , 2022, Nature Biotechnology.

[12]  King-Chuen Wu,et al.  Drug Repurposing: The Mechanisms and Signaling Pathways of Anti-Cancer Effects of Anesthetics , 2022, Biomedicines.

[13]  C. Crews,et al.  PROTACs: past, present and future. , 2022, Chemical Society reviews.

[14]  R. Webby,et al.  Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir. , 2022, Antiviral research.

[15]  Lihe Zhang,et al.  Discovery of Pentacyclic Triterpenoid PROTACs as a Class of Effective Hemagglutinin Protein Degraders. , 2022, Journal of medicinal chemistry.

[16]  Hai-Bing Zhou,et al.  Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus , 2022, Cell insight.

[17]  Zhenlong Liu,et al.  An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA , 2022, Nature communications.

[18]  L. Menéndez-Arias,et al.  Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity , 2022, Viruses.

[19]  Hualiang Jiang,et al.  Recent advances in predicting protein-protein interactions with the aid of artificial intelligence algorithms. , 2022, Current opinion in structural biology.

[20]  D. Langley,et al.  PROTAC targeted protein degraders: the past is prologue , 2022, Nature Reviews Drug Discovery.

[21]  E. Gilboa,et al.  Author Correction: Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity , 2021, Nature Communications.

[22]  Y. Bi,et al.  Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses. , 2021, Journal of medicinal chemistry.

[23]  P. Zhan,et al.  Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins , 2021, Acta pharmaceutica Sinica. B.

[24]  Xiaojiao Li,et al.  Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects , 2021, Expert opinion on investigational drugs.

[25]  Qingxin Li,et al.  Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets. , 2021, Current topics in medicinal chemistry.

[26]  Yong Gu Lee,et al.  Design of Neuraminidase-Targeted Imaging and Therapeutic Agents for the Diagnosis and Treatment of Influenza Virus Infections. , 2021, Bioconjugate chemistry.

[27]  Y. Xiong,et al.  Advancing targeted protein degradation for cancer therapy , 2021, Nature Reviews Cancer.

[28]  Jinyun Dong,et al.  PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy , 2021, Frontiers in Pharmacology.

[29]  R. Webby,et al.  The evolution and future of influenza pandemic preparedness , 2021, Experimental & Molecular Medicine.

[30]  E. Taioli,et al.  Informing the global COVID‐19 response by estimating excess deaths in Italy during the COVID‐19 and 1918 influenza pandemics , 2021, Journal of medical virology.

[31]  David F. Boyd,et al.  Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract , 2021, Nature Reviews Microbiology.

[32]  L. Bonnac,et al.  Broad-Spectrum Antiviral Strategies and Nucleoside Analogues , 2021, Viruses.

[33]  S. Cusack,et al.  Influenza Virus RNA-Dependent RNA Polymerase and the Host Transcriptional Apparatus. , 2021, Annual review of biochemistry.

[34]  J. Huskens,et al.  A Dynamic, Supramolecular View on the Multivalent Interaction between Influenza Virus and Host Cell. , 2021, Small.

[35]  A. Kishimura,et al.  Synthesis and biological evaluation of a monocyclic Fc-binding antibody-recruiting molecule for cancer immunotherapy. , 2021, RSC medicinal chemistry.

[36]  E. De Clercq,et al.  Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. , 2021, Chemical Society reviews.

[37]  N. Knoers,et al.  Drug Repurposing for Rare Diseases. , 2021, Trends in pharmacological sciences.

[38]  F. Stellacci,et al.  Broad‐Spectrum Antiviral Agents Based on Multivalent Inhibitors of Viral Infectivity , 2021, Advanced healthcare materials.

[39]  Hao Tan,et al.  Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with in vivo antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses , 2021, Emerging microbes & infections.

[40]  R. Haag,et al.  Heteromultivalent topology-matched nanostructures as potent and broad-spectrum influenza A virus inhibitors , 2021, Science Advances.

[41]  P. Low,et al.  A universal dual mechanism immunotherapy for the treatment of influenza virus infections , 2020, Nature Communications.

[42]  Xiangshu Xiao,et al.  PROTACs to address the challenges facing small molecule inhibitors. , 2020, European journal of medicinal chemistry.

[43]  Meihua Lin,et al.  Rationally Designed Multivalent Aptamers Targeting Cell Surface for Biomedical Applications. , 2020, ACS applied materials & interfaces.

[44]  Jiyeon Kim,et al.  Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo , 2020, Scientific Reports.

[45]  A. Dueñas-González,et al.  Perspectives on Drug Repurposing. , 2020, Current medicinal chemistry.

[46]  N. Friedman,et al.  Selective flexible packaging pathways of the segmented genome of influenza A virus , 2020, Nature Communications.

[47]  E. D. da Silva-Júnior,et al.  Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections. , 2020, Current medicinal chemistry.

[48]  Luis W Dominguez,et al.  Research and Development Costs of New Drugs. , 2020, JAMA.

[49]  R. Mosa,et al.  Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases , 2020, Drug design, development and therapy.

[50]  C. del Rio,et al.  Comparison of Estimated Excess Deaths in New York City During the COVID-19 and 1918 Influenza Pandemics , 2020, JAMA network open.

[51]  A. Dömling,et al.  Covalent inhibitors: a rational approach to drug discovery , 2020, RSC medicinal chemistry.

[52]  S. Ludwig,et al.  Dissecting the mechanism of signaling-triggered nuclear export of newly synthesized influenza virus ribonucleoprotein complexes , 2020, Proceedings of the National Academy of Sciences.

[53]  Maicol Bissaro,et al.  The rise of molecular simulations in fragment-based drug design (FBDD): an overview , 2020, Drug Discovery Today.

[54]  Priti Jain,et al.  Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies. , 2020, Current molecular medicine.

[55]  R. Haag,et al.  Adaptive Flexible Sialylated Nanogels as Highly Potent Influenza A Virus Inhibitors , 2020, Angewandte Chemie.

[56]  Yongcheng Song,et al.  Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy , 2020, Journal of Hematology & Oncology.

[57]  Yu Ding,et al.  Emerging New Concepts of Degrader Technologies , 2020, Trends in Pharmacological Sciences.

[58]  S. H. Barghout.  Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer. , 2020, Anti-cancer agents in medicinal chemistry.

[59]  S. De Carlo,et al.  Phage capsid nanoparticles with defined ligand arrangement block influenza virus entry , 2020, Nature Nanotechnology.

[60]  Jun Wang,et al.  Put a cork in it: Plugging the M2 viral ion channel to sink influenza , 2020, Antiviral Research.

[61]  A. Hurt,et al.  Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations is more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy. , 2020, Antiviral research.

[62]  T. Hennet,et al.  Antiviral potential of 3′-sialyllactose- and 6′-sialyllactose-conjugated dendritic polymers against human and avian influenza viruses , 2020, Scientific Reports.

[63]  E. Fodor,et al.  Structure and Function of the Influenza Virus Transcription and Replication Machinery. , 2019, Cold Spring Harbor perspectives in medicine.

[64]  P. Král,et al.  Multivalent Cluster Nanomolecules for Inhibiting Protein-Protein Interactions. , 2019, Bioconjugate chemistry.

[65]  Jingtong Zheng,et al.  Role of the Innate Cytokine Storm Induced by the Influenza A Virus. , 2019, Viral immunology.

[66]  Katelyn M. Gostic,et al.  Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics , 2019, PLoS pathogens.

[67]  G. Gao,et al.  Naproxen Exhibits Broad Anti-influenza Virus Activity in Mice by Impeding Viral Nucleoprotein Nuclear Export. , 2019, Cell reports.

[68]  S. Laufer,et al.  Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. , 2018, Journal of medicinal chemistry.

[69]  C. Tabata,et al.  Highly aggressive plasmablastic neoplasms in patients with rheumatoid arthritis treated with methotrexate. , 2019, International immunopharmacology.

[70]  C. Wagner,et al.  Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density. , 2018, Journal of the American Chemical Society.

[71]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[72]  Dhilon S. Patel,et al.  Synthetic Immunotherapeutics against Gram-negative Pathogens. , 2018, Cell chemical biology.

[73]  Edward C Hutchinson.  Influenza Virus. , 2018, Trends in microbiology.

[74]  R. Lonsdale,et al.  Structure-based design of targeted covalent inhibitors. , 2018, Chemical Society reviews.

[75]  R. Gregory,et al.  Design, Synthesis, and in vitro Evaluation of Multivalent Drug Linkers for High‐Drug‐Load Antibody–Drug Conjugates , 2018, ChemMedChem.

[76]  Shanshan Gu,et al.  PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery , 2018, BioEssays : news and reviews in molecular, cellular and developmental biology.

[77]  R. Netz,et al.  Quantitative Prediction of Multivalent Ligand-Receptor Binding Affinities for Influenza, Cholera, and Anthrax Inhibition. , 2018, ACS nano.

[78]  Andrew G. Watts,et al.  Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives. , 2018, Journal of medicinal chemistry.

[79]  T. Ross,et al.  Towards a universal influenza vaccine: different approaches for one goal , 2018, Virology Journal.

[80]  Chunlong Ma,et al.  In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. , 2018, Journal of medicinal chemistry.

[81]  Nicolas Moitessier,et al.  Covalent inhibitors design and discovery. , 2017, European journal of medicinal chemistry.

[82]  Yuan Sun,et al.  Designing multi-targeted agents: An emerging anticancer drug discovery paradigm. , 2017, European journal of medicinal chemistry.

[83]  G. Boivin,et al.  A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir , 2017, Open forum infectious diseases.

[84]  W. DeGrado,et al.  An M2‐V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine‐sensitive and ‐resistant influenza A viruses , 2017, Antiviral research.

[85]  J. Neyts,et al.  Structure‐activity relationship studies on a Trp dendrimer with dual activities against HIV and enterovirus A71. Modifications on the amino acid , 2017, Antiviral research.

[86]  Chunlong Ma,et al.  Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzuki-Miyaura Cross-Coupling Reaction. , 2017, Journal of medicinal chemistry.

[87]  Xiuli Wu,et al.  Progress of small molecular inhibitors in the development of anti-influenza virus agents , 2017, Theranostics.

[88]  Antoine M. van Oijen,et al.  Mechanisms of influenza viral membrane fusion. , 2016, Seminars in cell & developmental biology.

[89]  B. Lina,et al.  Functional balance between neuraminidase and haemagglutinin in influenza viruses. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[90]  B. Haynes,et al.  Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection , 2016, Nature Reviews Drug Discovery.

[91]  Shinji Watanabe,et al.  Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. , 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[92]  Seth M. Cohen,et al.  Fragment-Based Identification of Influenza Endonuclease Inhibitors , 2016, Journal of medicinal chemistry.

[93]  Min Liu,et al.  Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor. , 2016, Angewandte Chemie.

[94]  K. Meng,et al.  Pentacyclic triterpenes grafted on CD cores to interfere with influenza virus entry: A dramatic multivalent effect. , 2016, Biomaterials.

[95]  W. DeGrado,et al.  Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel. , 2016, Journal of medicinal chemistry.

[96]  Dusanka Janezic,et al.  H274Y's Effect on Oseltamivir Resistance: What Happens Before the Drug Enters the Binding Site , 2016, J. Chem. Inf. Model..

[97]  J. Winum,et al.  Emerging trends in enzyme inhibition by multivalent nanoconstructs. , 2015, Organic & biomolecular chemistry.

[98]  Weiqi Wang,et al.  New small-molecule drug design strategies for fighting resistant influenza A , 2015, Acta pharmaceutica Sinica. B.

[99]  Kai Ludwig,et al.  Size dependence of steric shielding and multivalency effects for globular binding inhibitors. , 2015, Journal of the American Chemical Society.

[100]  R. Lamb,et al.  Flipping in the Pore: Discovery of Dual Inhibitors That Bind in Different Orientations to the Wild-Type versus the Amantadine-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel , 2014, Journal of the American Chemical Society.

[101]  A. Hurt.  The epidemiology and spread of drug resistant human influenza viruses. , 2014, Current opinion in virology.

[102]  Arturo Ferreira,et al.  Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy , 2014, Biological Research.

[103]  Markus K. Dahlgren,et al.  Illuminating HIV gp120-Ligand Recognition through Computationally-Driven Optimization of Antibody-Recruiting Molecules. , 2014, Chemical science.

[104]  Christopher G. Parker,et al.  Exploring binding and effector functions of natural human antibodies using synthetic immunomodulators. , 2013, ACS chemical biology.

[105]  Steven F. Baker,et al.  Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors. , 2013, ACS chemical biology.

[106]  R. Pieters,et al.  Bridging lectin binding sites by multivalent carbohydrates. , 2013, Chemical Society reviews.

[107]  Andrew G. Watts,et al.  Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity , 2013, Science.

[108]  C. Di Primo,et al.  Structure-Based Discovery of the Novel Antiviral Properties of Naproxen against the Nucleoprotein of Influenza A Virus , 2013, Antimicrobial Agents and Chemotherapy.

[109]  G. Gao,et al.  Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors , 2013, Nature Communications.

[110]  E. Fodor,et al.  Nuclear import of the influenza A virus transcriptional machinery. , 2012, Vaccine.

[111]  R. Rabadán,et al.  Viral reassortment as an information exchange between viral segments , 2012, Proceedings of the National Academy of Sciences.

[112]  David A Spiegel,et al.  Grand challenge commentary: Synthetic immunology to engineer human immunity. , 2010, Nature chemical biology.

[113]  Yoshihiro Kawaoka,et al.  Cellular networks involved in the influenza virus life cycle. , 2010, Cell host & microbe.

[114]  A. Ciucci,et al.  Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational Level* , 2009, The Journal of Biological Chemistry.

[115]  W. DeGrado,et al.  Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. , 2009, Journal of the American Chemical Society.

[116]  Z. Zhou,et al.  Influenza virus morphogenesis and budding , 2009, Virus Research.

[117]  K. Pabbaraju,et al.  Adamantane resistance in circulating human influenza A viruses from Alberta, Canada (1970-2007). , 2008, Antiviral research.

[118]  Michael K Gilson,et al.  Evaluation of the substrate envelope hypothesis for inhibitors of HIV‐1 protease , 2007, Proteins.

[119]  M. Dickson,et al.  Key factors in the rising cost of new drug discovery and development , 2004, Nature Reviews Drug Discovery.

[120]  Christopher J. Schofield,et al.  Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL , 2002, Nature.

[121]  R. Read,et al.  Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands , 2000, Nature.

[122]  O. Terrier,et al.  Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means. , 2021, Advances in experimental medicine and biology.

[123]  T. Wolff,et al.  Topology-matching design of an influenza neutralizing spiky nano-inhibitor with a dual mode of action , 2020 .

[124]  Chi‐Huey Wong,et al.  Enhanced anti-influenza agents conjugated with anti-inflammatory activity. , 2012, Journal of medicinal chemistry.

[125]  E. Domingo,et al.  Virus population dynamics, fitness variations and the control of viral disease: an update. , 2001, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.